Clinical Trials on Platelet-Rich Plasma

Total 5620 results

UCB Biopharma SRL

Active, not recruiting

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Chemotherapy-Induced Thrombocytopenia
University of Rochester

Recruiting

Study of Avatrombopag for Temozolomide-induced Thrombocytopenia in Glioma (APATIT-G)

Thrombocytopenia

United States
Sobi, Inc.

Completed

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

Chemotherapy-induced Thrombocytopenia

United States, China, Hungary, Poland, Russian Federation, Serbia, Ukraine
Guangzhou First People's Hospital
LanZhou University; Sun Yat-sen University; The Third Affiliated Hospital of... and other collaborators

Completed

HPA Antibodies and the Distribution of Antigen and Antibodies

Blood Disease | Antibody-mediated Rejection | Platelet Refractoriness

China
Beijing Northland Biotech. Co., Ltd.

Completed

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Chemotherapy-induced Thrombocytopenia

China
Institute of Hematology & Blood Diseases Hospital

Completed

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Thrombocytopenia

China
BioMAS Ltd

Terminated

Application of AS101 for the Treatment of Thrombocytopenia in Solid Tumor Patients

Chemotherapy Induced Thrombocytopenia

Israel
Finnish Institute for Health and Welfare
University of Oslo; Academy of Finland; The Finnish Funding Agency for Technology... and other collaborators

Completed

The Effect of Berry Consumption on Indicators of Cardiovascular Disease Risk

Inflammation | Blood Pressure | Platelet Function

Finland
Assaf-Harofeh Medical Center

Completed

Omega 3 Action on Cardiovascular Risk Factors in Patients Treated With Statins

Inflammation | Blood Pressure | Endothelial Function | Platelet Function
Celgene

Terminated

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Pathologic Processes | Fibrosis | Respiratory Tract Diseases | Lung Diseases | Idiopathic Pulmonary Fibrosis | Lung Diseases, Interstitial | Idiopathic Interstitial Pneumonias

United States, Australia, Colombia, United Kingdom, Russian Federation, Brazil, Germany, Canada, Greece, Romania, Taiwan, Turkey, Ukraine
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
University of Alabama at Birmingham

Completed

Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation

Therapeutic Plasma Exchange | Anticoagulant Therapy

United States
Alison Gernand
Penn State University

Completed

Cyclic Variation in Micronutrient Concentrations and Plasma Volume

Menstrual Cycle | Plasma Volume | Micronutrients

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation (PCL-2)

Plasma Cell Leukemia
National Cerebral and Cardiovascular Center

Recruiting

REASSURE-NIRS Registry (REASSURENIRS)

Lipid-Rich Atherosclerosis of Coronary Artery

Japan
Qilu Pharmaceutical Co., Ltd.

Recruiting

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia

China
SuxiaLuo

Recruiting

A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province

Carcinoma;Blood

China
Qilu Pharmaceutical Co., Ltd.

Completed

Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia

Chemotherapy-induced Thrombocytopenia

China
Medical College of Wisconsin
Mallinckrodt; Versiti; Clinical & Translational Science Institute of Southeast...

Completed

Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation

Inflammation | Platelet Dysfunction

United States
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.

Chemotherapy-Induced Thrombocytopenia

China
Faculty Hospital Kralovske Vinohrady

Completed

The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry (LAPCOR)

Platelet Aggregation Onhibitors

Czechia
University of Rochester

Completed

Effects of Pioglitazone on Platelet Function (UHEM08014)

Healthy | Diabetes | Platelet Function

United States
Ono Pharma USA Inc

Terminated

A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia

United States, Korea, Republic of, Russian Federation
Chitwan Medical College

Completed

Association Between Preoperative HALP and Immediate Postoperative Outcomes

Mortality | Platelets | Morbidity | Hemoglobins | Lymphocytes | Albumins | Whipples Procedure

Nepal
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia | Loss of Chromosome 17p | Autologous Hematopoietic Stem Cell Transplant Recipient

United States
Duke University
National Heart, Lung, and Blood Institute (NHLBI); Vanderbilt University; National...

Terminated

Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias

Idiopathic Interstitial Pneumonias

United States
Wake Forest University Health Sciences
Carolinas Medical Center

Completed

Correcting Platelet Dysfunction After Traumatic Brain Injury

Traumatic Brain Injury | Platelet Dysfunction

United States
National Human Genome Research Institute (NHGRI)

Completed

Genetic Analysis of Gray Platelet Syndrome

Myelofibrosis | Genetic Linkage

United States
University of Jordan
Nutritional Fundamentals for Health

Completed

Determination of Pharmacokinetics of Different Curcuminoids Preparations: Pilot Study

Plasma Levels of Different Curcuminoids Preparations

Jordan
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

Plasma Cell Leukemia

China
Hikari Dx, Inc.
Fujimori Kogyo Co., Ltd.

Recruiting

Clinical Performance Evaluation of T-TAS®01 HD Chip

Thrombocytopenia

United States
The First Affiliated Hospital of Soochow University

Recruiting

Construction of a Database for TMA

Thrombotic Microangiopathies

China
University Hospital, Toulouse
French network for inherited hemorragic diseases; National Reference Centre...

Recruiting

Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia (ELPOT)

Thrombocytopenia

France
U.S. Army Medical Research and Development Command

Completed

Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets

Thrombocytopenia

United States
Peking University People's Hospital
Nanfang Hospital of Southern Medical University; The First Affiliated Hospital...

Terminated

Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy

Thrombocytopenia | Stem Cell Transplant Complications

China
Hamilton Health Sciences Corporation
University Health Network, Toronto; Dartmouth-Hitchcock Medical Center; Ottawa... and other collaborators

Terminated

Strategies for Transfusion of Platelets (SToP)

Thrombocytopenia

United States, Norway, Canada
Roswell Park Cancer Institute

Recruiting

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of California, San Francisco
Janssen Pharmaceuticals; Multiple Myeloma Research Foundation

Terminated

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
Takeda

Active, not recruiting

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
OHSU Knight Cancer Institute
Sanofi; Oregon Health and Science University

Active, not recruiting

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States

Clinical Trials on Platelet-Rich Plasma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations